Zevra Therapeutics (ZVRA) Accounts Payables (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Accounts Payables came in at $11.7 million in Q1 2026, down 34.41% YoY from $17.8 million in Q1 2025, and up 0.78% on a QoQ basis from $11.6 million in Q4 2025.
Zevra Therapeutics (ZVRA) Accounts Payables (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Accounts Payables data on file, last reported at $11.7 million in Q1 2026.
- Quarterly Accounts Payables fell 34.41% year-over-year to $11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (down 34.41% YoY) and the FY2025 annual result came in at $11.6 million, down 54.44% from the prior year.
- Accounts Payables grew to $11.7 million in Q1 2026, from $11.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $28.4 million in Q4 2023 to a low of $393000.0 in Q1 2023.
- A 5-year average of $14.0 million and a median of $12.4 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables sank 84.78% — and 2024, when it soared 5697.71%.
- Tracing ZVRA's Accounts Payables over 5 years: stood at $3.6 million in 2022, then surged by 686.57% to $28.4 million in 2023, then decreased by 10.38% to $25.5 million in 2024, then slumped by 54.44% to $11.6 million in 2025, then climbed by 0.78% to $11.7 million in 2026.
- The last three Accounts Payables figures came in at $11.7 million (Q1 2026), $11.6 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 13.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.96 Mn |
| Mar 31, 2026 | 11.69 Mn |
| Dec 31, 2025 | 11.60 Mn |
| Sep 30, 2025 | 11.07 Mn |
| Jun 30, 2025 | 15.84 Mn |
| Mar 31, 2025 | 17.82 Mn |
| Dec 31, 2024 | 25.46 Mn |
| Sep 30, 2024 | 24.46 Mn |
| Jun 30, 2024 | 20.45 Mn |
| Mar 31, 2024 | 22.79 Mn |
| Dec 31, 2023 | 28.40 Mn |
| Sep 30, 2023 | 13.08 Mn |
| Jun 30, 2023 | 10.51 Mn |
| Mar 31, 2023 | 393,000.00 |
| Dec 31, 2022 | 3.61 Mn |
| Jun 30, 2022 | 3.60 Mn |
| Mar 31, 2022 | 2.58 Mn |
| Dec 31, 2021 | 3.04 Mn |
| Sep 30, 2021 | 2.09 Mn |
| Jun 30, 2021 | 2.97 Mn |